A genetic analysis of integrin function

Glanzmann thrombasthenia in vitro

Elizabeth K. Baker, Eileen Collins Tozer, Martin Pfaff, Sanford J. Shattil, Joseph C Loftus, Mark H. Ginsberg

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Glanzmann thrombasthenia, an inherited bleeding disorder, can be caused by a defect or deficiency in platelet integrin α(IIb)β3 (GPIIb-IIIa). Studies of thrombasthenia variants have facilitated identification of sites involved in the functions of α(IIb)β3 and other integrins. Such sites include those that bind ligand and those that participate in the 'activation' of α(IIb)β3 required for high affinity binding of ligands such as fibrinogen or PAC1, a monoclonal antibody. Here we describe the isolation of such variants, created in vitro with Chinese hamster ovary cells that express an activated form of α(IIb)β3. These cells were exposed to a mutagen, ethyl methane sulfonate, and variants that lost the capacity to bind PAC1 were isolated by fluorescence-activated cell sorting. These variants were grouped into three phenotypic classes. One comprised integrin mutations that disrupt ligand binding function; a second comprised mutations that interfere with the capacity of cells to activate the integrin. Most of these activation-defective mutations were in the integrin cytoplasmic domain, but surprisingly, several were caused by mutations affecting three closely spaced residues in the β3 extracellular domain. A third class of mutants exhibited a defect in integrin activation not ascribable to changes in the integrin sequence. Thus, these may represent mutated signaling molecules required for integrin activation. This unbiased genetic approach provides new insights into the structural basis of integrin function and may assist in identifying the cellular events that regulate integrin function.

Original languageEnglish (US)
Pages (from-to)1973-1978
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume94
Issue number5
DOIs
StatePublished - Mar 4 1997
Externally publishedYes

Fingerprint

Thrombasthenia
Integrins
Mutation
Ligands
In Vitro Techniques
Methane
Mutagens
Cricetulus
Fibrinogen
Ovary
Flow Cytometry
Blood Platelets
Monoclonal Antibodies

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

A genetic analysis of integrin function : Glanzmann thrombasthenia in vitro. / Baker, Elizabeth K.; Tozer, Eileen Collins; Pfaff, Martin; Shattil, Sanford J.; Loftus, Joseph C; Ginsberg, Mark H.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 94, No. 5, 04.03.1997, p. 1973-1978.

Research output: Contribution to journalArticle

Baker, Elizabeth K. ; Tozer, Eileen Collins ; Pfaff, Martin ; Shattil, Sanford J. ; Loftus, Joseph C ; Ginsberg, Mark H. / A genetic analysis of integrin function : Glanzmann thrombasthenia in vitro. In: Proceedings of the National Academy of Sciences of the United States of America. 1997 ; Vol. 94, No. 5. pp. 1973-1978.
@article{8fdeddd612074187a80e704224757021,
title = "A genetic analysis of integrin function: Glanzmann thrombasthenia in vitro",
abstract = "Glanzmann thrombasthenia, an inherited bleeding disorder, can be caused by a defect or deficiency in platelet integrin α(IIb)β3 (GPIIb-IIIa). Studies of thrombasthenia variants have facilitated identification of sites involved in the functions of α(IIb)β3 and other integrins. Such sites include those that bind ligand and those that participate in the 'activation' of α(IIb)β3 required for high affinity binding of ligands such as fibrinogen or PAC1, a monoclonal antibody. Here we describe the isolation of such variants, created in vitro with Chinese hamster ovary cells that express an activated form of α(IIb)β3. These cells were exposed to a mutagen, ethyl methane sulfonate, and variants that lost the capacity to bind PAC1 were isolated by fluorescence-activated cell sorting. These variants were grouped into three phenotypic classes. One comprised integrin mutations that disrupt ligand binding function; a second comprised mutations that interfere with the capacity of cells to activate the integrin. Most of these activation-defective mutations were in the integrin cytoplasmic domain, but surprisingly, several were caused by mutations affecting three closely spaced residues in the β3 extracellular domain. A third class of mutants exhibited a defect in integrin activation not ascribable to changes in the integrin sequence. Thus, these may represent mutated signaling molecules required for integrin activation. This unbiased genetic approach provides new insights into the structural basis of integrin function and may assist in identifying the cellular events that regulate integrin function.",
author = "Baker, {Elizabeth K.} and Tozer, {Eileen Collins} and Martin Pfaff and Shattil, {Sanford J.} and Loftus, {Joseph C} and Ginsberg, {Mark H.}",
year = "1997",
month = "3",
day = "4",
doi = "10.1073/pnas.94.5.1973",
language = "English (US)",
volume = "94",
pages = "1973--1978",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "5",

}

TY - JOUR

T1 - A genetic analysis of integrin function

T2 - Glanzmann thrombasthenia in vitro

AU - Baker, Elizabeth K.

AU - Tozer, Eileen Collins

AU - Pfaff, Martin

AU - Shattil, Sanford J.

AU - Loftus, Joseph C

AU - Ginsberg, Mark H.

PY - 1997/3/4

Y1 - 1997/3/4

N2 - Glanzmann thrombasthenia, an inherited bleeding disorder, can be caused by a defect or deficiency in platelet integrin α(IIb)β3 (GPIIb-IIIa). Studies of thrombasthenia variants have facilitated identification of sites involved in the functions of α(IIb)β3 and other integrins. Such sites include those that bind ligand and those that participate in the 'activation' of α(IIb)β3 required for high affinity binding of ligands such as fibrinogen or PAC1, a monoclonal antibody. Here we describe the isolation of such variants, created in vitro with Chinese hamster ovary cells that express an activated form of α(IIb)β3. These cells were exposed to a mutagen, ethyl methane sulfonate, and variants that lost the capacity to bind PAC1 were isolated by fluorescence-activated cell sorting. These variants were grouped into three phenotypic classes. One comprised integrin mutations that disrupt ligand binding function; a second comprised mutations that interfere with the capacity of cells to activate the integrin. Most of these activation-defective mutations were in the integrin cytoplasmic domain, but surprisingly, several were caused by mutations affecting three closely spaced residues in the β3 extracellular domain. A third class of mutants exhibited a defect in integrin activation not ascribable to changes in the integrin sequence. Thus, these may represent mutated signaling molecules required for integrin activation. This unbiased genetic approach provides new insights into the structural basis of integrin function and may assist in identifying the cellular events that regulate integrin function.

AB - Glanzmann thrombasthenia, an inherited bleeding disorder, can be caused by a defect or deficiency in platelet integrin α(IIb)β3 (GPIIb-IIIa). Studies of thrombasthenia variants have facilitated identification of sites involved in the functions of α(IIb)β3 and other integrins. Such sites include those that bind ligand and those that participate in the 'activation' of α(IIb)β3 required for high affinity binding of ligands such as fibrinogen or PAC1, a monoclonal antibody. Here we describe the isolation of such variants, created in vitro with Chinese hamster ovary cells that express an activated form of α(IIb)β3. These cells were exposed to a mutagen, ethyl methane sulfonate, and variants that lost the capacity to bind PAC1 were isolated by fluorescence-activated cell sorting. These variants were grouped into three phenotypic classes. One comprised integrin mutations that disrupt ligand binding function; a second comprised mutations that interfere with the capacity of cells to activate the integrin. Most of these activation-defective mutations were in the integrin cytoplasmic domain, but surprisingly, several were caused by mutations affecting three closely spaced residues in the β3 extracellular domain. A third class of mutants exhibited a defect in integrin activation not ascribable to changes in the integrin sequence. Thus, these may represent mutated signaling molecules required for integrin activation. This unbiased genetic approach provides new insights into the structural basis of integrin function and may assist in identifying the cellular events that regulate integrin function.

UR - http://www.scopus.com/inward/record.url?scp=0031055333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031055333&partnerID=8YFLogxK

U2 - 10.1073/pnas.94.5.1973

DO - 10.1073/pnas.94.5.1973

M3 - Article

VL - 94

SP - 1973

EP - 1978

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 5

ER -